Abstract
Oral or intraperitoneal administration of bis(3-methylsulfonyloxypropyl)amine p-toluenesulfonate (864-T) and N-methyl-N, N-bis(3-methylsulfonyloxypropyl)amine 4, 4'-biphenyldisulfonate (838-D) for 3 consecutive days before or after immunization suppressed the number of 19S hemolysin plaque-forming cells (HPFC) in the spleen as well as the circulating antibodies, hemagglutinin and hemolysin, of mice on day 4 after immunization with sheep red blood cells. In single administration, the maximum inhibition was found on day 0 in 864-T and 838-D, on day 2 in cyclophosphamide, and on day 3 in busulfan. 864-T and 838-D were classified in the different type from cyclophosphamide or busulfan. Seven-S HPFC were not suppressed by 864-T, 838-D, nitrogen mustard N-oxide, busulfan, or 6-mercaptopurine in the administration for 3 consecutive days from day 0 or from day 4, and only cyclophosphamide inhibited it when administered from day 4. 864-T and 838-D did not affect the carbon clearance in mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
